

Safety Data Sheet

0.01mol/L tetrabutylammonium bromide solution-6 quinolones mixed in acetonitrile



Version : V2.0.0.1

Report No. : BWN6296-2016-MSDS-EP

Creation Date : 2026/01/09

Revision Date : -

***Prepared in accordance with EU REACH Regulation (REACH 1907/2006 with amendment 2020/878)**

1 Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product Name	0.01mol/L tetrabutylammonium bromide solution-6 quinolones mixed in acetonitrile
Cat No.	BWN6296-2016
CAS No.	Not applicable
EC No.	Not applicable
Molecular Formula	Not applicable
REACH Registration Number	-
UFI	No information available

1.2 Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Please consult manufacturer.
Uses advised against	Please consult manufacturer.

1.3 Details of the supplier of the Safety Data Sheet

Name of the company	Weiyel Inc
Address of the company	Hedian Light Industrial Park, Chengguan Town, Shangcheng County, Xinyang City, Henan Province, China
Post code	465350
Telephone number	010-58103678
Fax number	010-84840368
E-mail address	info@weiyel.com

1.4 Emergency telephone number

Emergency telephone number	010-58103678
Opening hours	24h

2 Hazards identification

2.1 CLP classification according to Regulation (EC) No. 1272/2008 with amendment 2023/707

According to Regulation (EC) No 1272/2008 and its amendments. Not classified as a dangerous substance.

2.2 Label elements

Hazard pictograms	Not applicable
Signal word	Not applicable

Hazard statements

Hazard statements	Not applicable
-------------------	----------------

Precautionary statements

◆ Prevention

Prevention	Not applicable
------------	----------------

◆ Response

Response	Not applicable
----------	----------------

◆ Storage

Storage	Not applicable
---------	----------------

◆ Disposal

Disposal	Not applicable
----------	----------------

2.3 Other hazards

◆ Results of PBT and vPvB assessment

Component	Results of PBT and vPvB assessment [according to (EC) No 1907/2006]
Norfloxacin	Insufficient information, temporarily unable to evaluate
3-Quinolincarboxylic acid , 1-cyclopropyl-6-fluoro-1,4 -dihydro-4-oxo-7-(1-piper zinyl)-	Insufficient information, temporarily unable to evaluate
Enrofloxacin	Insufficient information, temporarily unable to evaluate
Ofloxacin	Insufficient information, temporarily unable to evaluate
Oxolinic acid	Insufficient information, temporarily unable to evaluate
Flumequine	Insufficient information, temporarily unable to evaluate

◆ Results of endocrine disrupting properties assessment

Component	Results of endocrine disrupting properties assessment [according to (EU) No 2017/2100 or (EU) No 2018/605]
Norfloxacin	Insufficient information, temporarily unable to evaluate
3-Quinolincarboxylic acid , 1-cyclopropyl-6-fluoro-1,4 -dihydro-4-oxo-7-(1-piper zinyl)-	Insufficient information, temporarily unable to evaluate
Enrofloxacin	Insufficient information, temporarily unable to evaluate
Ofloxacin	Insufficient information, temporarily unable to evaluate
Oxolinic acid	Insufficient information, temporarily unable to evaluate
Flumequine	Insufficient information, temporarily unable to evaluate

◆ Other

Other	Not applicable.
-------	-----------------

3 Composition/information on ingredients

3.1 Substance

Not applicable

3.2 Mixture

Component	Weight % content(or range)	Classification according to Regulation (EC) No. 1272/2008 with amendment 2023/707 [CLP]	Specific Conc. Limits, M-factors
0.01 mol/L Tetrabutylammonium Bromide Solution - Acetonitrile CAS : - EC : - Index No. : -	99.994	No information available	-
Norfloxacin CAS : 70458-96-7 EC : 274-614-4 Index No. : -	0.001	Serious eye damage/irritation, Category 2, H319	-
3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-(1-piperazinyl)- CAS : 85721-33-1 EC : 617-751-0 Index No. : -	0.001	Not Classified	-
Enrofloxacin CAS : 93106-60-6 EC : 618-911-2 Index No. : -	0.001	Acute Toxicity - Oral, Category 4, H302; Sensitization - skin, Category 1, H317; Sensitization - respiratory, Category 1, H334	-
Ofloxacin CAS : 82419-36-1 EC : 680-263-1 Index No. : -	0.001	Acute Toxicity - Oral, Category 4, H302; Skin Corrosion/Irritation, Category 2, H315; Serious eye damage/irritation, Category 2, H319; Acute Toxicity - Inhalation, Category 4, H332	-
Oxolinic acid CAS : 14698-29-4 EC : 238-750-8 Index No. : -	0.001	Acute Toxicity - Oral, Category 4, H302	-
Flumequine CAS : 42835-25-6 EC : 255-962-6 Index No. : -	0.001	Not Classified	-

4 First-aid measures

4.1 Description of first aid measures

General advice	Immediate medical attention is required. Show this safety data sheet (SDS) to the doctor in attendance.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician if feel uncomfortable.
Skin contact	Take off contaminated clothing and shoes immediately. Wash off with plenty of soap and water for at least 15 minutes and consult a physician if feel uncomfortable.

Ingestion	Never give anything by mouth to an unconscious person. Call a physician or Poison Control Center immediately.
Inhalation	Move victim into fresh air. If breathing is difficult, give oxygen. Do not use mouth to mouth resuscitation if victim ingested or inhaled the substance. If not breathing, give artificial respiration and consult a physician immediately.
Protecting of first-aiders	Ensure that medical personnel are aware of the substance involved. Take precautions to protect themselves and prevent spread of contamination.

4.2 Most important symptoms/effects, acute and delayed

1	Substance accumulation, in the human body, may occur and may cause some concern following repeated or long-term occupational exposure.
---	--

4.3 Indication of any immediate medical attention and special treatment needed

1	Treat symptomatically.
2	Symptoms may be delayed.

5 Fire-fighting measures

5.1 Extinguishing media

Suitable extinguishing media	Use extinguishing media suitable for surrounding area.
Unsuitable extinguishing media	There is no restriction on the type of extinguisher which may be used.

5.2 Specific hazards arising from the substance or mixture

1	Development of hazardous combustion gases or vapor possible in the event of fire.
2	May expand or decompose explosively when heated or involved in fire.

5.3 Advice for firefighters

1	As in any fire, wear self-contained breathing apparatus (MSHA/NIOSH approved or equivalent) and full protective gear.
2	Fight fire from a safe distance, with adequate cover.
3	Prevent fire extinguishing water from contaminating surface water or the ground water system.

6 Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

1	Use personal protective equipment, do not breathe gas/mist/vapour/spray.
2	Ensure adequate ventilation. Remove all sources of ignition. Take precautionary measures against static discharges.
3	Evacuate personnel to safe areas. Keep people away from and upwind of spill/leak.

6.2 Environmental precautions

1	Prevent further leakage or spillage if safe to do so.
2	Discharge into the environment must be avoided.

6.3 Methods and materials for containment and cleaning up

1	Cut off the source of the leak as much as possible.
2	Keep leaks in a ventilated place.
3	Absorb spilled material in dry sand or inert absorbent. In case of large amount of spillage, contain a spill by bunding.

4	Remove all sources of ignition. Use spark-proof tools and explosion-proof equipment.
5	Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and place in container.

6.4 Reference to other sections

1	Personal Protective Equipment advice is contained in Section 8 of the SDS.
2	Disposal considerations advice is contained in Section 13 of the SDS.

7 Handling and storage

7.1 Precautions for safe handling

◆ Protective measures

1	Handling is performed in a well ventilated place.
2	Wear suitable protective equipment.
3	Avoid contact with skin and eyes.

◆ Measures to prevent fire

1	Keep away from heat/sparks/open flames/ hot surfaces.
---	---

◆ Measures to prevent aerosol and dust generation

1	Not applicable.
---	-----------------

◆ Advice on general occupational hygiene

1	Wash hands and face after using the substances.
2	Replace the contaminated clothing immediately.

7.2 Conditions for safe storage, including any incompatibilities

1	Keep containers tightly closed.
2	Keep containers in a dry, cool and well-ventilated place.
3	Keep away from heat/sparks/open flames/hot surfaces.
4	Store away from incompatible materials and foodstuff containers.

7.3 Specific end use(s)

1	In addition to use mentioned in the Section 1.2, unforeseen other specific end uses.
---	--

8 Exposure controls/personal protection

8.1 Control parameters

◆ Occupational exposure limit values

Occupational Exposure limit values	No relevant regulations
---	-------------------------

◆ Biological limit values

Biological limit values	No relevant regulations
--------------------------------	-------------------------

◆ Monitoring methods

1	EN 14042 Workplace atmospheres. Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents.
2	GBZ/T 300 and GBZ/T 160 series standard Determination of toxic substances in workplace air.

◆ Derived No effect level (DNEL)

Component	Route of exposure	DNEL for Workers			
		Acute effects (local)	Acute effects (systemic)	Chronic effects (local)	Chronic effects (systemic)
0.01 mol/L Tetrabutylammonium Bromide Solution - Acetonitrile	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Norfloxacin	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
3-Quinolincarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Enrofloxacin	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Oxfloxacin	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Oxolinic acid	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available
Flumequine	Inhalation	No data available	No data available	No data available	No data available
	Oral	No data available	No data available	No data available	No data available
	Dermal	No data available	No data available	No data available	No data available

◆ Predicted No Effect Concentration (PNEC)

Predicted No Effect Concentration (PNEC)	No information available
---	--------------------------

8.2 Exposure controls

8.2.1 Engineering controls

1	Ensure adequate ventilation, especially in confined areas.
2	Ensure that eyewash stations and safety showers are close to the workstation location.
3	Use explosion-proof electrical/ventilating/lighting/equipment.
4	Set up emergency exit and necessary risk-elimination area.

8.2.2 Personal protection equipment

General requirement	No special requirements, please see the description below.
Eye protection	In general situation, eye protection is not needed. In the production process, when contacting with vapour or dust, tightly fitting safety goggles.
Hand protection	In general situation, hand protection is not needed.

Respiratory protection	In general situation, respiratory protection is not needed. If exposure limits are exceeded or if irritation or other symptoms are experienced, wear dust proof mask or gas defence mask.
Skin and body protection	In general situation, skin and body protection are not needed.

8.2.3 Environmental exposure controls

Environmental exposure controls	No information available
--	--------------------------

9 Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	clear or clear yellow liquid
Colour	clear or clear yellow liquid
Odor	No information available
Odor threshold	No information available
pH	No information available
Melting point/freezing point(°C)	No information available
Initial boiling point and boiling range(°C)	>35
Flash point(Closed cup, °C)	No information available
Evaporation rate	No information available
Flammability	No information available
Upper/lower explosive limits[%(v/v)]	Upper limit : No information available ; Lower limit : No information available
Vapor pressure	No information available
Vapor density(Air = 1)	No information available
Relative density(Water=1)	No information available
Solubility	No information available
n-octanol/water partition coefficient	No information available
Auto-ignition temperature(°C)	No information available
Decomposition temperature(°C)	No information available
Kinematic viscosity	No information available
Explosive properties	No information available
Oxidizing properties	No information available
Particle characteristics	Not applicable

9.2 Other information

9.2.1 Information with regard to physical hazard classes

Information with regard to physical hazard classes	No information available
---	--------------------------

9.2.2 Other safety characteristics

Other safety characteristics	No information available
-------------------------------------	--------------------------

10 Stability and reactivity

Stability and reactivity

10.1 Reactivity	Contact with incompatible substances can cause decomposition or other chemical reactions.
10.2 Chemical stability	Stable under proper operation and storage conditions.
10.3 Possibility of hazardous reactions	No information available.
10.4 Conditions to avoid	Incompatible materials, heat, flame and spark.
10.5 Incompatible materials	No information available.
10.6 Hazardous decomposition products	Under normal conditions of storage and use, hazardous decomposition products should not be produced.

11 Toxicological information**11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008 with amendment 2023/707**

0.01mol/L tetrabutylammonium bromide solution-6 quinolones mixed in acetonitrile	
Skin corrosion/irritation	Based on available data, the classification criteria are not met
Serious eye damage/irritation	Based on available data, the classification criteria are not met
Skin sensitization	Based on available data, the classification criteria are not met
Respiratory sensitization	Based on available data, the classification criteria are not met
Reproductive toxicity	Based on available data, the classification criteria are not met
STOT-single exposure	Based on available data, the classification criteria are not met
STOT-repeated exposure	Based on available data, the classification criteria are not met
Aspiration hazard	Based on available data, the classification criteria are not met
Germ cell mutagenicity	Based on available data, the classification criteria are not met

Acute toxicity

Component	LD₅₀(oral)	LD₅₀(dermal)	LC₅₀(inhalation,4h)
Oxolinic acid	525mg/kg(Rat)	> 2000mg/kg(Rat)	No information available

Carcinogenicity

Component	List of carcinogens by the IARC Monographs	Report on Carcinogens by NTP
0.01 mol/L Tetrabutylammonium Bromide Solution - Acetonitrile	Not Listed	Not Listed
Norfloxacin	Not Listed	Not Listed
3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-	Not Listed	Not Listed
Enrofloxacin	Not Listed	Not Listed
Ofloxacin	Not Listed	Not Listed

Oxolinic acid	Not Listed	Not Listed
Flumequine	Not Listed	Not Listed

11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

Component	Endocrine disrupting properties
Norfloxacin	No information available
3-Quinolincarboxylicacid , 1-cyclopropyl-6-fluoro-1,4 -dihydro-4-oxo-7-(1-pipera zinyl)-	No information available
Enrofloxacin	No information available
Ofloxacin	No information available
Oxolinic acid	No information available
Flumequine	No information available

11.2.2 Other Information

Other Information	See Section 11.1
-------------------	------------------

12 Ecological information

12.1 Toxicity

Acute aquatic toxicity

Acute aquatic toxicity	No information available
------------------------	--------------------------

Chronic aquatic toxicity

Chronic aquatic toxicity	No information available
--------------------------	--------------------------

12.2 Persistence and degradability

Persistence and degradability	No information available
-------------------------------	--------------------------

12.3 Bioaccumulative potential

Bioaccumulative potential	No information available
---------------------------	--------------------------

12.4 Mobility in soil

Mobility in soil	No information available
------------------	--------------------------

12.5 Results of PBT and vPvB assessment

Component	Results of PBT and vPvB assessment [according to (EC) No 1907/2006]
Norfloxacin	Insufficient information, temporarily unable to evaluate
3-Quinolincarboxylicacid , 1-cyclopropyl-6-fluoro-1,4 -dihydro-4-oxo-7-(1-pipera	Insufficient information, temporarily unable to evaluate

zinyl)-	
Enrofloxacin	Insufficient information, temporarily unable to evaluate
Ofloxacin	Insufficient information, temporarily unable to evaluate
Oxolinic acid	Insufficient information, temporarily unable to evaluate
Flumequine	Insufficient information, temporarily unable to evaluate

12.6 Endocrine disrupting properties

Component	Endocrine disrupting properties
Norfloxacin	No information available
3-Quinolinecarboxylic acid , 1-cyclopropyl-6-fluoro-1,4 -dihydro-4-oxo-7-(1-piper zinyl)-	No information available
Enrofloxacin	No information available
Ofloxacin	No information available
Oxolinic acid	No information available
Flumequine	No information available

12.7 Other adverse effects

	No information available
--	--------------------------

13 Disposal considerations

13.1 Waste treatment methods

Waste chemicals	Before disposal should refer to the relevant national and local laws and regulation. Recommend the use of incineration disposal.
Contaminated packaging	Containers may still present chemical hazard when empty. Keep away from hot and ignition source of fire. Return to supplier for recycling if possible.
Disposal recommendations	Refer to section waste chemicals and contaminated packaging.

14 Transport information

Label and Mark

Transporting Label	Not applicable
---------------------------	----------------

IMDG-CODE

IMDG-CODE	NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS
------------------	--

IATA-DGR

IATA-DGR	NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS
-----------------	--

UN-ADR

UN-ADR	NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS
---------------	--

Special precautions for user

Transport vehicles should be equipped with the appropriate variety and quantity of fire equipment and emergency equipment leakage during transport. Before transport, should be preceded by checking whether container integrity, sealing. The transport unit must be placarded and marked in accordance with relevant transporting requirements.

Maritime transport in bulk according to IMO instruments

- ◆ Transport in bulk according to Annex II of MARPOL and the IBC code

Not Available

- ◆ Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Not Available

- ◆ Transport in bulk in accordance with the IGC Code

Not Available

15 Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

International chemical inventory

Component	A	B	C	D	E	F	G	H	I	J	K	L	M
0.01 mol/L Tetrabutylammonium Bromide Solution - Acetonitrile	x	x	x	x	x	x	x	x	x	x	x	x	x
Norfloxacin	√	√	x	√	x	√	√	x	x	x	√	√	√
3-Quinolonecarboxylicacid 1-cyclopropyl-6-fluoro-1,4- dihydro-4-oxo-7-(1-pipera ziny)-	√	x	x	x	x	x	x	x	x	x	√	√	√
Enrofloxacin	√	x	x	x	√	x	√	x	x	x	√	√	√
Ofloxacin	√	x	x	x	x	x	√	x	x	x	√	√	√
Oxolinic acid	x	√	x	√	√	x	√	x	√	√	x	√	√
Flumequine	x	√	x	x	x	x	√	x	x	x	x	√	√

- [A] China Inventory of Existing Chemical Substances(IECSC)
 [B] European Inventory of Existing Commercial Chemical Substances(EC inventory)
 [C] United States Toxic Substances Control Act Inventory(TSCA)
 [D] Canadian Domestic Substances List(DSL)
 [E] New Zealand Inventory of Chemicals(NZIoC)
 [F] Philippines Inventory of Chemicals and Chemical Substances(PICCS)
 [G] Korea Existing Chemicals Inventory(KECL)
 [H] Australian. Inventory of Industrial Chemical (AIICS)
 [I] Japan Inventory of Existing & New Chemical Substances(ENCS)
 [J] Thailand Existing Chemicals Inventory(TECI)
 [K] Mexico National Inventory of Chemical Substances (INSQ)
 [L] Russia Inventory of Existing Substances(DRAFT)
 [M] Inventory of Existing Chemical Substances in Taiwan, China (TCSI)

List of Chemical Substances under International Conventions

Component	A	B	C
-----------	---	---	---

0.01 mol/L Tetrabutylammonium Bromide Solution - Acetonitrile	×	×	×
Norfloxacin	×	×	×
3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4- dihydro-4-oxo-7-(1-piperazinyl)-	×	×	×
Enrofloxacin	×	×	×
Ofloxacin	×	×	×
Oxolinic acid	×	×	×
Flumequine	×	×	×

[A] The Montreal Protocol on Substances that Deplete the Ozone Layer

[B] Stockholm Convention on Persistent Organic Pollutants (POPs)

[C] Rotterdam Convention on the prior informed consent procedure for certain hazardous chemicals and pesticides in international trade

European chemical inventory

Component	A	B	C	D	E	F	G	H	I
0.01 mol/L Tetrabutylammonium Bromide Solution - Acetonitrile	×	×	×	×	×	×	×	×	×
Norfloxacin	×	×	×	√	×	×	×	×	×
3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4- oxo-7-(1-piperazinyl)-	×	×	×	√	×	×	×	×	×
Enrofloxacin	×	×	×	√	×	×	×	×	×
Ofloxacin	×	×	×	×	×	×	×	×	×
Oxolinic acid	×	×	×	√	×	×	×	×	×
Flumequine	×	×	×	√	×	×	×	×	×

[A] Candidate list of Substances of Very High Concern for authorization under EU REACH regulation

[B] Substances requiring authorisation under EU REACH regulation

[C] Substances restricted under EU REACH

[D] Pre-registered substances under EU REACH

[E] Registered substances under EU REACH

[F] Substance Evaluation – CoRAP under EU REACH

[G] List of priority substances under EU water policy (Directive 2455/2001/EC)

[H] Substances subject to POPs Regulation

[I] Substances proposed as POPs

Note:

“√” Indicates that the substance included in the regulations.

“x” No data or not included in the regulations.

German water hazard class(WGK)

Component	WGK	Remark
3-Quinolincarboxylicacid, 1-cyclopropyl-6-fluoro-1,4-dihydr o-4-oxo-7-(1-piperazinyl)-	WGK 2	
Ofloxacin	WGK 3	

【WGK 1】	slightlyhazardous to water
【WGK 2】	obviouslyhazardous to water
【WGK 3】	highly hazardous to water
【nwg】	non-hazardous to water
【awg】	hazardous to water in general

German technical instructions on air quality control(TA LUFT)

No information available

German technical rules for hazardous substances(TRGS)

No information available

15.2 Chemical safety assessment

No Chemical Safety Assessment has been carried out for this substance/mixture by the supplier.

16 Other information

Information on revision

Creation Date	2026/01/09
Revision Date	-
Reason for revision	-

Reference

- [1] IPCS: The International Chemical Safety Cards (ICSC), website: <http://www.ilo.org/dyn/icsc/showcard.home>.
- [2] IARC, website: <http://www.iarc.fr/>.
- [3] OECD: The Global Portal to Information on Chemical Substances, website: <https://www.echemportal.org/echemportal/>.
- [4] CAMEO Chemicals, website: <http://cameochemicals.noaa.gov/search/simple>.
- [5] NLM: ChemIDplus, website: <http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp>.
- [6] EPA: Integrated Risk Information System, website: <http://cfpub.epa.gov/iris/>.
- [7] U.S. Department of Transportation: ERG, website: <http://www.phmsa.dot.gov/hazmat/library/erg>.
- [8] Germany GESTIS-database on hazard substance, website: <http://gestis-en.itrust.de/>.

Abbreviations and acronyms

CAS	Chemical Abstracts Service	UN	The United Nations
PC-STEL	Short term exposure limit	OECD	Organization for Economic Co-operation and Development
PC-TWA	Time Weighted Average	IMDG-CODE	International Maritime Dangerous Goods CODE
MAC	Maximum Allowable Concentration	IARC	International Agency for Research on Cancer
DNEL	Derived No Effect Level	ICAO	International Civil Aviation Organization
PNEC	Predicted No Effect Concentration	IATA	International Air Transportation Association
NOEC	No Observed Effect Concentration	ACGIH	American Conference of Governmental Industrial Hygienists
LC ₅₀	Lethal Concentration 50%	NFPA	National Fire Protection Association
LD ₅₀	Lethal Dose 50%	NTP	National Toxicology Program
EC ₅₀	Effective Concentration 50%	PBT	Persistent, Bioaccumulative, Toxic
EC _x	Effective Concentration X%	vPvB	very Persistent, very Bioaccumulative
P _{OW}	Partition coefficient Octanol: Water	CMR	Carcinogens, mutagens or substances toxic to reproduction
BCF	Bioconcentration factor	RPE	Respiratory Protective Equipment
ED	Endocrine disruptor		

Disclaimer

This Safety Data Sheet (SDS) was prepared according to REACH Regulation. The data included was derived from international authoritative database and provided by the enterprise. Other information was based on the present state of our knowledge. We try to ensure the correctness of all information. However, due to the diversity of information sources and the limitations of our knowledge, this document is only for user's reference. Users should make their independent judgment of suitability of this information for their particular purposes. We do not assume responsibility for loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of the product.